How to Reconstitute MOTS-c: Storage, Stability, and Dosing After Mixing

What Is MOTS-c and Why Reconstitution Matters

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded in mitochondrial DNA and first characterized by Lee et al. In a 2015 Cell paper that identified it as a regulator of glucose metabolism and insulin sensitivity. Unlike most peptides encoded in nuclear DNA, MOTS-c originates from the mitochondrial genome, making it genuinely unusual among metabolic signaling molecules.

For women, that metabolic angle matters. MOTS-c activates the AMPK pathway, mimicking the cellular energy-sensing effects of exercise and caloric restriction. Preclinical data show particular relevance for insulin-resistant phenotypes that track closely with PCOS, perimenopause, and postmenopausal metabolic shift. A 2019 study in Aging found that MOTS-c levels decline with age and correlate inversely with visceral adiposity in women, suggesting an endogenous deficiency model that researchers are actively investigating.

Because MOTS-c is supplied commercially as a lyophilized (freeze-dried) powder, it cannot be injected directly. Proper reconstitution is the single most important technical step. Get the diluent wrong and you risk peptide degradation; get the storage wrong after mixing and you lose potency before the vial is finished. Both errors carry real cost, and the second is far more common in practice.

Supplies You Need Before You Start

Gather everything before opening a vial. Touching an open vial without all supplies ready is a contamination risk.

Mandatory items

• MOTS-c lyophilized vial (confirmed not expired, powder visible and white)
• Bacteriostatic water for injection, USP (30 mL multi-dose vial)
• Two U-100 insulin syringes: one for drawing diluent, one for injecting
• Alcohol swabs (70% isopropyl)
• A clean, flat, well-lit surface
• A fine-tip permanent marker and labeling tape

Why bacteriostatic water, not sterile water

USP <797> compounding standards require that multi-dose peptide vials use an antimicrobial preservative in the diluent to suppress microbial growth over repeated punctures. Bacteriostatic water contains 0.9% benzyl alcohol, which achieves this. Sterile water for injection is preservative-free and is appropriate only for single-use preparations discarded within hours. Because most MOTS-c vials are accessed over days to weeks, bacteriostatic water is the correct choice for home use.

Saline (0.9% sodium chloride) is sometimes used in clinical settings but carries no preservative benefit over bacteriostatic water for multi-dose peptides and may affect the peptide's solubility at higher concentrations.

Step-by-Step Reconstitution Protocol

Step 1. Inspect the vial

Before you touch anything, hold the lyophilized vial up to the light. The powder should be uniformly white, dry, and adherent to the bottom or sides of the glass. Any yellow discoloration, visible moisture, or clumping suggests compromised storage. Discard the vial and contact your compounding pharmacy.

Step 2. Wipe both septa

Swab the rubber septum of the MOTS-c vial and the bacteriostatic water vial with a fresh alcohol swab. Allow 15 to 30 seconds for the alcohol to dry fully before puncturing. Injecting wet alcohol into either vial denatures the peptide and the preservative.

Step 3. Draw the diluent

Insert the insulin syringe needle through the center of the bacteriostatic water septum. Pull back the plunger to draw your target diluent volume (see the dosing calculator section below for exact volumes). Withdraw the syringe cleanly.

Step 4. Add diluent slowly down the vial wall

Insert the syringe needle through the center of the MOTS-c vial septum at a slight angle so the needle tip rests just inside the glass, not directly over the powder. Depress the plunger slowly, letting bacteriostatic water run down the inner wall of the vial rather than blasting the powder. Forcing liquid directly onto lyophilized peptide creates foam and mechanical shear that degrades fragile peptide bonds.

Step 5. Do not shake

Gently swirl the vial with two fingers using a slow circular motion for 20 to 30 seconds. The powder should dissolve into a clear, colorless solution. If you see cloudiness or particulate matter after 60 seconds of swirling, do not use the vial. Cloudiness indicates either peptide aggregation or microbial contamination.

Step 6. Label immediately

Write on the tape label: peptide name, concentration (mg/mL), date of reconstitution, and discard date (28 days from today). Affix it before the vial leaves your hand.

MOTS-c Dosing Calculator: Getting the Concentration Right

The math here is straightforward but worth doing carefully because the dose volume you draw from the reconstituted vial depends directly on the stock concentration you create.

The WomanRx MOTS-c Dilution Framework

| Vial Size | Diluent Added | Stock Concentration | Dose (5 mg) Drawn As | |-----------|--------------|--------------------|-----------------------| | 5 mg | 1.0 mL bacteriostatic water | 5 mg/mL | 1.0 mL (full U-100 syringe) | | 5 mg | 2.0 mL bacteriostatic water | 2.5 mg/mL | 1.0 mL = 2.5 mg; draw 2.0 mL for 5 mg | | 10 mg | 2.0 mL bacteriostatic water | 5 mg/mL | 1.0 mL = 5 mg | | 10 mg | 4.0 mL bacteriostatic water | 2.5 mg/mL | 1.0 mL = 2.5 mg |

Most compounding protocols for MOTS-c in women's metabolic health contexts use a 5 mg/mL stock (1 mL diluent per 5 mg powder). This keeps injection volumes at or below 1 mL per dose, which is the practical upper limit for comfortable subcutaneous injection at a single site.

If your prescriber has written a dose of 2 mg, use 2.5 mg/mL stock and draw 0.8 mL. Converting: (desired dose in mg) divided by (stock concentration in mg/mL) equals volume to draw in mL.

U-100 insulin syringes are calibrated in "units" where 100 units = 1 mL. So 10 units = 0.1 mL. At 5 mg/mL stock, each 10 units on the syringe = 0.5 mg MOTS-c. Write this conversion on the label for easy reference.

Storage and Stability After Reconstitution

Refrigerated stability (post-reconstitution)

Once reconstituted with bacteriostatic water, MOTS-c should be stored at 2 to 8°C (36 to 46°F) in the back of the refrigerator, not the door where temperature fluctuates. The FDA's guidance on compounded sterile preparations and USP <797> assign a beyond-use date of 28 days for multi-dose sterile preparations reconstituted with a preserved diluent (bacteriostatic water) stored under refrigeration. Mark your label accordingly and discard at day 28 regardless of remaining volume.

Peptide stability data more broadly show that most lyophilized peptides, once in solution, undergo accelerated aggregation and deamidation above 8°C. MOTS-c has not been the subject of independent published stability studies in solution as of early 2025. The 28-day refrigerated guideline is extrapolated from USP <797> standards and general peptide stability chemistry, not from MOTS-c-specific data. This is an evidence gap worth naming honestly.

Never freeze a reconstituted vial

Freezing causes ice crystal formation that physically disrupts peptide secondary structure. Lyophilized (unreconstituted) powder may be stored at , 20°C for 12 to 24 months, but once you add bacteriostatic water, the freezer is off-limits.

Protect from light

Peptide bonds are susceptible to UV photodegradation. Store the reconstituted vial in its original cardboard box or wrap the vial in foil. Do not leave it on a countertop near a window.

Room temperature during use

You may draw your dose and let the syringe sit at room temperature for 5 to 10 minutes before injecting to reduce injection-site discomfort. Do not leave the filled syringe at room temperature for more than 30 minutes.

Injection Technique: Subcutaneous Administration With an Insulin Syringe

MOTS-c is administered subcutaneously, meaning into the fat layer just beneath the skin, not into muscle.

Needle selection

A 29 to 31-gauge, 0.5-inch (12.7 mm) needle attached to a U-100 100-unit syringe is the standard choice. The short needle length is appropriate for subcutaneous depth at common injection sites in women. A 31-gauge needle causes less injection-site pain than larger gauges with no difference in pharmacokinetic absorption for peptides in this molecular weight range.

Site rotation

Rotate among the lower abdomen (at least 2 inches from the navel), outer thigh, and the back of the upper arm. Injecting the same site repeatedly causes lipohypertrophy, a localized fat accumulation that alters absorption unpredictably. Lipohypertrophy is documented in 30 to 40% of people who self-inject without rotating sites.

Injection steps

1. Wash hands for 20 seconds with soap and water.
2. Swab the chosen skin site with an alcohol wipe; let it dry for 15 seconds.
3. Pinch a fold of skin between thumb and forefinger.
4. Insert the needle at 45 to 90 degrees depending on body composition (45 degrees for leaner tissue, 90 degrees for more subcutaneous fat).
5. Depress the plunger slowly and steadily over 3 to 5 seconds.
6. Withdraw the needle at the same angle of insertion.
7. Apply gentle pressure with a clean cotton ball; do not rub.
8. Dispose of the needle in a sharps container immediately.

How Hormonal Life Stage Changes MOTS-c Use in Women

Reproductive years and PCOS

MOTS-c's primary mechanism, AMPK activation and improved insulin sensitivity, is directly relevant to PCOS. Women with PCOS have 30 to 50% lower insulin sensitivity compared with body-mass-index-matched controls without the condition. A 2019 murine study in PNAS showed MOTS-c administration reduced hyperandrogenemia and improved ovarian morphology in a PCOS-model mouse, though human trial data in women with PCOS remain absent as of 2025. This is a significant evidence gap. Any use in women with PCOS is currently off-label extrapolation from preclinical work.

Perimenopause

Estrogen exerts direct protective effects on mitochondrial function. As estrogen declines during perimenopause, mitochondrial efficiency drops and visceral fat accumulates, often faster than body weight changes would predict. Endogenous MOTS-c levels appear to track with estrogen decline based on the same 2019 Aging dataset. Some clinicians hypothesize that exogenous MOTS-c may partially compensate for this mitochondrial shift during the menopausal transition, but no randomized controlled trial has tested this in perimenopausal women. Metabolic clearance differences in this life stage are not yet characterized, so starting at the lower end of any prescribed dose range is prudent.

Post-menopause

The 2015 Cell study observed that older mice treated with MOTS-c showed reversal of age-related insulin resistance. Whether this translates to post-menopausal women is unknown. Post-menopausal women already on menopausal hormone therapy (MHT) may experience additive metabolic benefit given that estrogen itself improves insulin sensitivity, but interaction data do not exist.

Trying to conceive and fertility

No human fertility data exist for MOTS-c. Because MOTS-c affects AMPK signaling pathways that intersect with mTOR and reproductive axis regulation, use during active fertility treatment should be discussed explicitly with your reproductive endocrinologist. Do not self-start MOTS-c during an IVF cycle or while on ovulation induction protocols without specialist clearance.

Pregnancy, Lactation, and Contraception

MOTS-c is contraindicated in pregnancy. No human pregnancy safety data exist. MOTS-c has not been assigned an FDA pregnancy category because it is not an approved drug product; it is a compounded peptide used off-label. Animal reproductive toxicology studies have not been published in peer-reviewed literature as of early 2025.

AMPK activation, the primary mechanism of MOTS-c, has demonstrated complex effects on placental nutrient transport and trophoblast invasion in animal models. AMPK activators can restrict placental nutrient delivery when activated at high levels, which raises a theoretical fetal growth concern. This is preclinical extrapolation, not proven human teratogenicity, but the absence of safety data is itself a reason to avoid use.

If you are of reproductive age, use reliable contraception throughout any course of MOTS-c. Barrier methods plus a hormonal method, or an IUD, are appropriate. If you conceive unexpectedly while using MOTS-c, stop the peptide immediately and contact your OB-GYN.

Lactation. No data exist on MOTS-c transfer into human breast milk. The peptide's 16-amino-acid structure means it would likely be hydrolyzed in the neonatal gut if transferred, but "likely hydrolyzed" is not the same as "proven safe." The LactMed database does not carry an entry for MOTS-c. Avoid use while breastfeeding.

Who This Is Right For, and Who Should Wait

May be appropriate for

• Women with documented insulin resistance (confirmed by fasting insulin, HOMA-IR, or oral glucose tolerance test) in reproductive years or perimenopause, under prescriber supervision
• Post-menopausal women with metabolic syndrome features working with an obesity medicine or endocrinology specialist
• Women with PCOS whose glucose and insulin markers have not normalized with metformin and lifestyle change, in a monitored off-label context

Not appropriate for

• Pregnant women or those actively trying to conceive
• Breastfeeding women
• Women with active malignancy (AMPK pathways intersect with cellular proliferation signaling; theoretical concern without definitive human data)
• Women with hepatic impairment (peptide clearance is not characterized in this population)
• Anyone sourcing MOTS-c from an unverified vendor without a certificate of analysis confirming purity and sterility

A word on compounding pharmacy sourcing

MOTS-c is not FDA-approved. It is compounded by 503A or 503B pharmacies in the United States. FDA-registered 503B outsourcing facilities are subject to current good manufacturing practice (cGMP) inspection, which gives a higher confidence level in sterility and peptide purity than unregulated online vendors. Always ask your prescriber or pharmacy for the certificate of analysis (COA) showing identity testing, purity (HPLC), and endotoxin levels before accepting a vial.

Troubleshooting Common Reconstitution Problems

| Problem | Likely Cause | Action | |---------|-------------|--------| | Powder will not dissolve after 2 minutes of swirling | Insufficient diluent volume or peptide aggregation from freezer damage | Add 0.1 mL more bacteriostatic water; if still cloudy, discard | | Solution is cloudy or has visible particles | Contamination or peptide aggregation | Discard immediately | | Foam forms during mixing | Diluent added too quickly directly onto powder | Next vial: add slowly down the vial wall | | Vial appears empty but powder was visible on receipt | Lyophilized cake is very thin and adheres to glass; normal with low-fill vials | Use a magnifier; reconstitute as normal | | Injection site develops a firm nodule | Lipohypertrophy from repeated site use | Rotate sites; allow affected site 4 to 6 weeks to resolve |

Stability Red Flags: When to Discard Early

Discard the reconstituted vial before the 28-day mark if you observe any of the following:

• Cloudiness or color change (any yellow, pink, or brown tint)
• Visible particulate matter
• Unusual smell on opening (peptide solutions are nearly odorless)
• The vial was left at room temperature for more than 2 hours
• The vial was frozen accidentally
• The septum has been punctured more than 20 times (each puncture introduces a small contamination risk that compounds)